Managing Editor
@ShahidNShah
@ShahidNShah
Every clinic that sees people with diabetes has a version of the same patient. Sixty-something, A1c drifting around eight, burning and pins-and-needles in both feet that are worse at night. Gabapentin was started a year ago, the dose went up twice, and the honest answer to “is it helping?” is “a little, and it makes me foggy.” That patient is not waiting quietly for the next appointment. They are searching, reading forums, asking relatives, and very often trying something on their own.
For care teams, that gap between the visit and the search bar is where a lot of real decisions get made. It is worth understanding what patients find there and how practices can meet them before they find it.
The size of the problem
Peripheral neuropathy affects roughly half of people with long-standing diabetes, and a meaningful share of them have pain rather than just numbness. The American Diabetes Association lists gabapentinoids, SNRIs such as duloxetine, and tricyclic antidepressants as first-line options for painful diabetic neuropathy. All three help some patients a lot and many patients only partly. In trials, the number of people who need to be treated for one to get at least half of their pain relieved sits somewhere around six to eight for most of these drugs. Side effects such as dizziness, sleepiness and weight gain push others to stop.
Put those numbers together and a large group of patients ends up in the middle: diagnosed, treated, still uncomfortable, and quietly looking for more.
What patients search for when the medication falls short
Look at the questions people type after a disappointing follow-up and a pattern appears. They are rarely asking “what is neuropathy?” They already know. They ask whether a vitamin, an herb or a diet change will help, and whether it is safe with what they already take.
Alpha-lipoic acid, vitamin B12, turmeric, acetyl-L-carnitine and fish oil come up constantly. So do traditional remedies. On one Ayurveda Q&A platform, a typical thread comes from a patient whose gabapentin is no longer enough, and the conversation is about whether amla can help neuropathy pain in the foot and ankle, what dose people use and what to watch for with diabetes medication. The questions are specific, practical and often well informed. What these patients lack is someone who connects the answer to their own chart.
What the evidence actually says
The evidence for most supplements in neuropathy is modest and uneven. Alpha-lipoic acid has the most data, with several randomized trials showing small improvements in symptom scores, mostly with intravenous dosing. Vitamin B12 matters a great deal for one group in particular: people on long-term metformin, who are prone to deficiency that can mimic or worsen neuropathy. Checking B12 in that group is cheap and frequently overlooked.
Amla, the Indian gooseberry, is a different case. It is rich in vitamin C and polyphenols, and small studies suggest it may modestly improve fasting glucose and some markers of oxidative stress. That is a plausible reason it shows up in neuropathy conversations, since better glucose control slows nerve damage over time. There is no good trial showing that amla itself relieves neuropathic pain. Patients deserve to hear both halves of that sentence: the idea is not absurd, and it is not a substitute for treatment that works.
The safety questions are more pressing than the efficacy ones. Anything that lowers glucose can add to the effect of insulin or sulfonylureas. Some herbal products are concentrated extracts rather than food, and quality varies widely between brands. Patients on anticoagulants, those with advanced kidney disease and those taking several drugs at once need a real medication review, not a forum reply.
Where practices lose the patient
Most of these patients never tell their clinician what they are taking. Surveys of supplement users in the United States consistently find that a large share do not disclose use, usually because nobody asked or because they expect to be dismissed. The result is a medication list that is wrong in a way the EHR cannot see.
A few habits change that quickly:
- Ask the open question. “Are you taking anything else for the pain, including vitamins, herbs or teas?” gets far more honest answers than “any supplements?”
- Put supplements in the record. If the EHR has a structured field for them, use it. Interaction checking only works on what is entered.
- Close the loop between visits. Patient portals and secure messaging let people ask “is this safe with my metformin?” when they are deciding, not three months later.
- Treat the fundamentals hard. Glucose control, foot exams, footwear, sleep and activity do more for most patients than any single capsule.
Digital tools that help
There is an opening here for digital health vendors and the practices that use them. Symptom tracking between visits, simple pain and sleep diaries, and reminders for foot checks all give clinicians better data than a single in-office score. Integrating a supplement and interaction check into intake forms catches problems before the first prescription changes. Telehealth follow-ups make it realistic to adjust doses or switch drug classes when the first choice is not working, instead of waiting for the next quarterly visit.
Some patients will also want to explore integrative or traditional approaches with a qualified practitioner. Practices that can say “here is what we know, here is what to avoid with your medications, and here is how to tell me if it helps” keep those patients inside the care relationship rather than pushing them to manage it alone.
The takeaway for care teams
Painful diabetic neuropathy is common, undertreated and frustrating for everyone involved. When first-line medication only partly works, patients go looking for answers, and they will find plenty. The practices that do best are the ones that expect that search, ask about it without judgment, and give patients a fast, safe route back to someone who knows their history.
